JP2019513394A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513394A5
JP2019513394A5 JP2018553980A JP2018553980A JP2019513394A5 JP 2019513394 A5 JP2019513394 A5 JP 2019513394A5 JP 2018553980 A JP2018553980 A JP 2018553980A JP 2018553980 A JP2018553980 A JP 2018553980A JP 2019513394 A5 JP2019513394 A5 JP 2019513394A5
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
domain
isolated
callar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027754 external-priority patent/WO2017181101A1/en
Publication of JP2019513394A publication Critical patent/JP2019513394A/ja
Publication of JP2019513394A5 publication Critical patent/JP2019513394A5/ja
Priority to JP2022096329A priority Critical patent/JP2022133308A/ja
Priority to JP2024107077A priority patent/JP2024138334A/ja
Pending legal-status Critical Current

Links

JP2018553980A 2016-04-15 2017-04-14 キメラアロ抗原受容体t細胞の組成物および方法 Pending JP2019513394A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022096329A JP2022133308A (ja) 2016-04-15 2022-06-15 キメラアロ抗原受容体t細胞の組成物および方法
JP2024107077A JP2024138334A (ja) 2016-04-15 2024-07-03 キメラアロ抗原受容体t細胞の組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322937P 2016-04-15 2016-04-15
US62/322,937 2016-04-15
PCT/US2017/027754 WO2017181101A1 (en) 2016-04-15 2017-04-14 Compositions and methods of chimeric alloantigen receptor t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096329A Division JP2022133308A (ja) 2016-04-15 2022-06-15 キメラアロ抗原受容体t細胞の組成物および方法

Publications (2)

Publication Number Publication Date
JP2019513394A JP2019513394A (ja) 2019-05-30
JP2019513394A5 true JP2019513394A5 (OSRAM) 2020-05-28

Family

ID=60042268

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553980A Pending JP2019513394A (ja) 2016-04-15 2017-04-14 キメラアロ抗原受容体t細胞の組成物および方法
JP2022096329A Pending JP2022133308A (ja) 2016-04-15 2022-06-15 キメラアロ抗原受容体t細胞の組成物および方法
JP2024107077A Pending JP2024138334A (ja) 2016-04-15 2024-07-03 キメラアロ抗原受容体t細胞の組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022096329A Pending JP2022133308A (ja) 2016-04-15 2022-06-15 キメラアロ抗原受容体t細胞の組成物および方法
JP2024107077A Pending JP2024138334A (ja) 2016-04-15 2024-07-03 キメラアロ抗原受容体t細胞の組成物および方法

Country Status (10)

Country Link
US (2) US20190153064A1 (OSRAM)
EP (1) EP3443076A4 (OSRAM)
JP (3) JP2019513394A (OSRAM)
KR (1) KR20190003550A (OSRAM)
CN (1) CN109328230A (OSRAM)
AU (2) AU2017248817A1 (OSRAM)
CA (1) CA3020599A1 (OSRAM)
MX (1) MX2018012539A (OSRAM)
RU (1) RU2018140056A (OSRAM)
WO (1) WO2017181101A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019157496A1 (en) * 2018-02-12 2019-08-15 University Of Florida Researchfoundation, Inc. Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
SG11202102012SA (en) * 2018-08-28 2021-04-29 Pharos Vaccine Inc Improved lentiviral vector
SG11202101996QA (en) * 2018-08-28 2021-03-30 Immunotech Biopharm Co Ltd Improved therapeutic t cell
CN110903399B (zh) * 2018-09-17 2022-02-01 台湾中国医药大学附设医院 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物
AU2020272074A1 (en) * 2019-04-12 2021-11-25 The Trustees Of The University Of Pennsylvania Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins
JP7649755B2 (ja) * 2019-05-13 2025-03-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法
EP4055049A1 (en) * 2019-11-05 2022-09-14 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy of multiple myeloma
US20230183296A1 (en) * 2020-05-13 2023-06-15 Nanjing Legend Biotech Co., Ltd. Compositions and methods for reducing host rejection of allogeneic cells using simian icp47 and variants thereof
CN113646433B (zh) * 2020-07-16 2022-10-11 苏州博腾生物制药有限公司 靶向抗TNF-α抗体的组合物和方法
CN116157415A (zh) * 2020-09-03 2023-05-23 苏州博腾生物制药有限公司 靶向抗rh抗体的组合物和方法
CN114369168B (zh) * 2020-10-19 2024-08-30 南京卡提医学科技有限公司 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法
WO2022083590A1 (zh) * 2020-10-19 2022-04-28 南京卡提医学科技有限公司 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法
CN116103239A (zh) * 2021-11-11 2023-05-12 南京北恒生物科技有限公司 工程化免疫细胞及其用途
EP4611775A1 (en) * 2022-11-04 2025-09-10 The Children's Hospital Of Philadelphia Compositions and methods for b cell directed immunotherapies for anti-aav neutralizing alloantibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466A (en) 1837-11-20 Jordan l
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのrna干渉経路遺伝子
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
HK1047770A1 (zh) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN102574908B (zh) * 2009-08-27 2018-08-03 诺沃—诺迪斯克有限公司 组织因子向活化的血小板的靶向
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
ES2835232T3 (es) * 2012-07-13 2021-06-22 Univ Pennsylvania CART19 para la utilización en un método de reducción del número de células B normales para la inducción de tolerancia
WO2014160627A1 (en) * 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
US10301370B2 (en) * 2014-05-02 2019-05-28 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor T cells
JP2017521046A (ja) * 2014-05-08 2017-08-03 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 有害な免疫応答を処置するための寛容原性タンパク質療法としてのB細胞標的化抗原IgG融合物の使用
EP3384013A4 (en) * 2015-12-04 2019-07-10 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNOTOLERANCE

Similar Documents

Publication Publication Date Title
JP2019513394A5 (OSRAM)
JP2018508219A5 (OSRAM)
JP6664528B2 (ja) Cld18a2標的免疫エフェクター細胞及びその調製方法と使用
RU2018140056A (ru) Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена
JP2020511136A5 (OSRAM)
JP2024062986A (ja) 腫瘍微小環境を標的にするキメラ抗原受容体t細胞
TWI775768B (zh) 新穎t細胞受器及使用其之免疫治療
EP3914611B1 (en) Receptors providing targeted costimulation for adoptive cell therapy
JP2020114264A5 (OSRAM)
KR102235202B1 (ko) T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car)
JP2025032089A (ja) 腫瘍微小環境を標的とするキメラ抗原受容体
JP2023036657A (ja) 修飾されたt細胞及びその使用方法
JP2024156654A (ja) 新規操作t細胞受容体およびそれを使用した免疫療法
JP2017537919A5 (OSRAM)
JP2018029594A5 (OSRAM)
JP2016520074A5 (OSRAM)
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
RU2017133637A (ru) Иммуномодулирующие слитые белки и пути их применения
TW202206453A (zh) 表現嵌合抗原受體之病毒特異性免疫細胞
JP2019530431A5 (OSRAM)
JP2015513920A5 (OSRAM)
EP3568466A1 (en) Targeted t cells with cytotoxicity toward immunosuppressive cells
JP7483746B2 (ja) Magea1特異的t細胞受容体およびその使用
JP2025107358A (ja) 細胞
CA3173527A1 (en) Methods for generating engineered memory-like nk cells and compositions thereof